Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 2 days ago
AHA 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter ablation of AF, left… View more

Anticoagulation

Electrophysiology & Arrhythmia
2 Trials That Will Change My Practice with Prof Rasha Al-Lamee
Author(s): Rasha Al-Lamee Added: 1 week ago
TCT 2025 - In this comprehensive highlights video from TCT 2025, Prof Rasha Al-Lamee (Imperial College Healthcare NHS Trust, UK) delivers an expert analysis of the groundbreaking late-breaking trials that are set to reshape interventional cardiology practice.Join Prof Al-Lamee as she breaks down the pivotal studies driving innovation in cardiovascular care and discusses their implications for… View more

Intervention
TCT 25: Seven-Year Follow-up of the PARTNER 3 Trial
Author(s): Michael J Mack Added: 1 week ago
TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114)… View more

Imaging & Diagnostics

Intervention
TCT 25: 5 Trials That Will Change My Practice with Dr Mirvat Alasnag
Author(s): Mirvat Alasnag Added: 2 weeks ago
TCT 2025 - In this insightful highlights video from TCT 2025, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) provides expert commentary on the most impactful late-breaking clinical trials presented at this year's conference.The commentary distills the most important late-breaking trials in structural cardiology, coronary interventions, and artificial intelligence presented at TCT 2025… View more

Digital Health

Guidelines & Statements
ESC 25: The SEMA-VR CardioLink-15 Trial
Author(s): Subodh Verma Added: 2 months ago
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
ESC 25: The STEEER-AF Trial
Author(s): Dipak Kotecha Added: 2 months ago
ESC Congress 2025 - Exploratory findings from STEEER-AF suggest that a comprehensive educational programme for stroke prevention and rhythm control therapy improved outcomes for patients with atrial fibrillation.Dr Dipak Kotecha (University of Birmingham, Birmingham, UK) joins us to discuss findings from the STEEER-AF (NCT04396418) cluster randomised trial by the ESC and EHRA. The prospective,… View more

Electrophysiology & Arrhythmia
ESC 25: The CARUSO Trial
Author(s): Tiziana Claudia Aranzulla Added: 2 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more

Intervention

Prevention & Chronic Conditions
ESC 25: 4 Heart Failure Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 2 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial… View more

Anticoagulation

Heart Failure
ESC 25: TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
Author(s): Philipp Lurz Added: 2 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation… View more

Intervention
TCT 25 Structural Interventions Highlights
Author(s): Nadira Hamid , Rahul P Sharma Added: 1 week ago
TCT 2025 — Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr Rahul P Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and… View more

Intervention